SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- The global next generation sequencing market size is expected to reach USD 23.7 billion by 2027, expanding at a CAGR of 11.7%, according to a new report by Grand View Research, Inc. Numerous advantages offered by high throughput sequencing over other genetic technologies such as sanger-seq and microarray is one of the key driving forces of the market for Next Generation Sequencing (NGS). Furthermore, increasing availability of low input DNA sampling methods that decrease the overall operational costs is anticipated to accelerate the use of next generation sequencing across various research and clinical applications.
Key suggestions from the report:
- In 2019, oncology was estimated as the application with the largest revenue share in the market for next generation sequencing
- This can be attributed to the fact that the technology has been largely adopted to decipher the link between cancer and genetics
- Moreover, NGS-based genetic testing for cancer predisposition can significantly improve the health outcome and reduce the mortality rate, thereby driving adoption in this segment
- The targeted sequencing segment has dominated the revenue share owing to its various benefits over the whole genome segment with respect to the depth of coverage and multiplexing capacities
- Significant price drop in sequencing the whole genome is anticipated to drive the segment at a lucrative growth rate
- Based on workflow, sequencing accounted for the major revenue share in 2019 in the market for next generation sequencing and is anticipated to maintain its dominance over the forecast period
- Being a key step, the end-users are making major investments in the seq-step, compared to sample preparation and data analysis
- Moreover, the key developers are engaged in introducing new seq-platforms with enhanced capabilities and efficiency. These factors have led the segment in terms of revenue over the past years
- Academic research entities are the largest end-users in terms of revenue generation owing to the high penetration of seq-technology in research activities
- On the other hand, this technology is making continued growth in clinical research and within clinical settings
- A substantial number of researchers are engaged in conducting translational research to accelerate the adoption of seq-technology in clinical diagnostics
- North American accounted for the maximum revenue share owing to the presence of integrated platform base in U.S.
- Presence of Illumina, the major player of next generation sequencing market for U.S. is another major factor that has driven the revenue share of this region in the past years
- Asia Pacific is projected to mark fastest growth owing to the increase in number of domestic developers in China coupled with the expansion of molecular diagnostics area
- Some major participants in the market for next generation sequencing are Illumina Inc.; F Hoffman-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; and BGI
- The companies are collaborating with diagnostic players to extend the use of their platforms in clinical settings
- For instance, Illumina has partnered with China's KingMed Diagnostics for use of its platform in oncology and hereditary disease testing.
Read 267 page research report with ToC on "Next Generation Sequencing Market Size, Share & Trends Analysis Report By Application (HLA Typing, Consumer Genomics), By Technology, By Workflow, By End Use, By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market/
Technology offered by New England Biolabs that employs magnetic beads in the template assembly process is anticipated to significantly improve the sample preparation protocols for next generation sequencing. Furthermore, recent technological advancements such as the use of Laboratory Information Management System (LIMS) for genome library automation allow next generation sequencing in a single day at a reasonable cost. These advancements are anticipated to proliferate the number of users of next generation sequencing over the forecast period.
This technology has captured the attention of several companies and investors operating across various domains including basic research, drug discovery and development, reproductive health, and consumer genomics. In addition, the plummeting cost and the added value of next generation sequencing data over conventional ones is anticipated to positively impact the diversification of this technology in other clinical areas, resulting into a lucrative revenue growth.
Grand View Research has segmented the global next generation sequencing market based on application, technology, workflow, end use, and region:
- NGS Application Outlook (Revenue, USD Million, 2016 - 2027)
- Oncology
- Diagnostics and Screening
- Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Other Diagnostics
- Research Diagnostics
- Clinical Investigation
- Infectious Diseases
- Idiopathic Diseases
- Inherited Diseases
- Non-Communicable/Other Diseases
- Reproductive Health
- NIPT
- Aneuploidy
- Microdeletions
- PGT
- Newborn Genetic Screening
- Single Gene Analysis
- HLA Typing /Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
- NGS Technology Outlook (Revenue, USD Million, 2016 - 2027)
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- DNA-based
- RNA-based
- NGS Workflow Outlook (Revenue, USD Million, 2016 - 2027)
- Pre-sequencing
- NGS Library Preparation Kits
- Semi-automated Library Preparation
- Automated Library Preparation
- Clonal Amplification
- Sequencing
- NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS End-use Outlook (Revenue, USD Million, 2016 - 2027)
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Other Users
- NGS Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Middle East & Africa
- South Africa
Find more research reports on Biotechnology Industry, by Grand View Research:
- Biomaterials Market - Biocompatibility, low toxicity, and renewable nature of polymeric biomaterials make them potent drug delivery agents in controlled and targeted drug delivery, thus providing lucrative opportunities for biomaterials market growth.
- Downstream Processing Market - The growing demand for advanced technologies in the purification of recombinant proteins produced by animal cell cultures to create high-value products of modern biotechnology propels downstream processing market growth.
- Stem Cells Market - Advances in tissue engineering strategies hold the potential to draw attention to the treatment of several chronic disorders. Automation in adult and cord blood processing and storage is expected to drive stem cells market growth significantly.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
